CABAZITAXEL Accord conc perf 60 mg/3ml 3 ml
7680682990016
CH-68299
L01CD04
07.16.1.
Reimbursement limitations:
CABAZACCORD2
En association avec la prednisone ou la prednisolone, pour le traitement de patients atteints d'un …
1 / 3
google
Details
- Product number
- 6829901
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- cabazitaxelum 60 mg, ethanolum anhydricum 1185 mg, polysorbatum 80, acidum citricum q.s. ad pH, ad solutionem pro 3 ml.
Articles (1)
Cabazitaxel Accord 60 mg/3 ml, Konzentrat zur Herstellung einer Infusionslösung
Konzentrat
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
60.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
1185.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 2690.90
Specialties list
Yes
Generic
Yes
Reimbursement limitation
SL addition date:
01/11/2021
Authorization holder
Accord Healthcare AG
4103 Bottmingen
Authorization information
- Swissmedic authorization number
- 68299
- Drug name
- Cabazitaxel Accord, Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- KOINF
- ATC Code
- L01CD04
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 15/07/2021
- Authorization expiration date
- 14/07/2026
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- CABAZITAXEL Accord conc perf 60 mg/3ml 3 ml
- Description (DE)
- CABAZITAXEL Accord Inf Konz 60 mg/3ml 3 ml
- Market launch
- 15/07/2021
- Narcotic (BTM)
- No